Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 8/2007

01-08-2007 | Review Article

Viscosupplementation with Hyaluronans for Osteoarthritis of the Knee

Clinical Efficacy and Economic Implications

Author: Dr David D. Waddell

Published in: Drugs & Aging | Issue 8/2007

Login to get access

Abstract

Treatment with intra-articular viscosupplementation with hyaluronan (hyaluronic acid) and its derivatives is an important component of the management of osteoarthritis (OA) of the knee. Several intra-articular hyaluronan formulations are now available that vary in their physical properties, duration of effect and treatment schedules.
Although aspects regarding their mechanism of action are not completely understood, numerous clinical trials, systematic reviews and meta-analyses have confirmed the efficacy of intra-articular hyaluronan therapies for relieving OA-related pain and improving joint function. Data indicate that intra-articular hyaluronan preparations provide OA pain relief that is comparable to or greater than that observed with conventional treatment, NSAID medications, intra-articular corticosteroids, arthroscopic lavage, physical therapy and exercise. Other studies indicate that multiple courses of hyaluronan are effective.
Intra-articular hyaluronan formulations are well tolerated and are associated with a low incidence of adverse effects, usually localised to the injected joint. Local adverse events associated with intra-articular hyaluronan products are typically mild to moderate in severity, benign and transient, although their aetiology is unknown.
The cost effectiveness of intra-articular hyaluronan has been demonstrated, but only in a limited number of studies. Cost savings with intra-articular hyaluronan can also be realised with reduction of NSAID medication use and the possibility of delaying total knee replacement, which can reduce the need for costly revision procedures. Because different intra-articular hyaluronan formulations require different numbers of injections and office visits, are associated with variable treatment costs, and provide varying degrees of efficacy, not all intra-articular hyaluronan formulations may be equally cost effective over time.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults: United States, 1999. MMWR 2001; 50: 120–5
2.
Dillon CF, Rasch EK, Gu Q, et al. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health And Nutrition Examination Survey 1991–1994. J Rheumatol 2006; 33(11): 2271–9PubMed
3.
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000; 43: 1905–15CrossRef
4.
Rodriguez-Monguio R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003; 21: 623–50PubMedCrossRef
5.
Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–99PubMedCrossRef
6.
7.
American Pain Society. Guidelines for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. 2nd ed. Glenview (IL): American Pain Society, 2002
8.
Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group [published erratum in J Rheumatol 1999; 26: 1216]. J Rheumatol 1998; 25: 2203–12PubMed
9.
Balazs EA, Watson D, Duff IF, et al. Hyaluronic acid in synovial fluid: I. Molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum 1967; 10: 357–76PubMedCrossRef
10.
Mazzucco D, Scott R, Spector M. Composition of joint fluid in patients undergoing total knee replacement and revision arthroplasty: correlation with flow properties. Biomaterials 2004; 25: 4433–45PubMedCrossRef
11.
Kaiyama J, Uzuki M. Alteration of hyaluronic acid property in synovial fluid of patients with osteoarthritis. J Iwate Med Assoc 2006; 58: 9–21
12.
Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int 1987; 7: 113–22PubMedCrossRef
13.
Bagga H, Burkhardt D, Sambrook P, et al. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol 2006; 33: 946–50PubMed
14.
Synvisc® product information. Cambridge (MA): Genzyme Biosurgery, 2003
15.
Hyalgan® product information. Bridgewater (NJ): Sanofi-Synthelabo, 2001
16.
Supartz® product information. Tokyo: Seikagaku Corporation, 2001
17.
Orthovisc® product information. Woburn (MA): Anika Pharmaceuticals, 2004
18.
Euflexxa™ prescribing information. Suffern (NY): Ferring Pharmaceuticals, 2005
19.
Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee (review). Cochrane Database Syst Rev 2006; (2): CD005321
20.
Drug topics redbook [CD-ROM]. Montvale (NJ): Medical Economics, 2006 Nov
21.
Rules and regulations. December 1, 2006. Federal Register 2006; 71(231): 69803, 70003
22.
Neustadt D, Caldwell J, Bell M, et al. Clinical effects of intraarticular injection of high molecular weight hyaluronan (Or-throvisc®) in osteoarthritis of the knee: a randomized, controlled, multicenter trial. J Rheumatol 2005; 32: 1928–36PubMed
23.
Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2006; 14: 154–62PubMedCrossRef
24.
Lussier A, Cividino AA, McFarlane CA, et al. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996; 23: 1579–85PubMed
25.
Wobig M, Beks P, Dickhut A, et al. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol 1999; 5: S24–31
26.
Evanich JD, Evanich CJ, Wright MB, et al. Efficacy of intraarticular hyaluronic acid injections in knee osteoarthritis. Clin Orthop Relat Res 2001; 390: 173–81PubMedCrossRef
27.
Waddell DD, Bricker D. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg 2006; 19: 19–27PubMed
28.
Carrabba MP, Paresce E, Angelini M, et al. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995; 15: 25–31
29.
Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology (Oxf) 1999; 38: 602–7CrossRef
30.
Jubb RW, Piva S, Beinat L, et al. A one-year, randomised, placebo (saline) controlled clinical trial of 500–730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract 2003; 57: 467–74PubMed
31.
Lohmander LS, Dalen N, Englund G, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis 1996; 55: 424–31PubMedCrossRef
32.
Day R, Brooks P, Conaghan PG, et al. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. J Rheumatol 2004; 31: 775–82PubMed
33.
Brandt KD, Block JA, Michalski JP, et al. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis: ORTHOVISC Study Group. Clin Orthop Relat Res 2001; (385): 130–43
34.
Grecomoro G, Martorana U, Di Marco C. Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo. Pharmatherapeutica 1987; 5: 137–41PubMed
35.
Wobig M, Dickhut A, Maier R, et al. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998; 20: 410–23PubMedCrossRef
36.
Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 1994; 55: 220–32CrossRef
37.
Henderson EB, Smith EC, Pegley F, et al. Intra-articular injections of 750 kDa hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis 1994; 53: 529–34PubMedCrossRef
38.
Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis: a controlled, randomized, double-blind, parallel-design multicentre study. Rheumatol (Oxf) 2002; 41: 1240–8CrossRef
39.
Tamir E, Robinson D, Koren R, et al. Intra-articular hyaluronan injections for the treatment of osteoarthritis of the knee: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 2001; 19: 265–70PubMedCrossRef
40.
Lo GH, LaValley M, McAlindon T, et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2004; 290: 3115–21CrossRef
41.
Wang CT, Lin J, Chang CJ, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: a meta-analysis of randomized controlled trials. J Bone Joint Surg Am 2004; 86–A: 538–45PubMed
42.
Arrich J, Piribauer F, Mad P, et al. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005; 172: 1039–43PubMedCrossRef
43.
Modawal A, Ferrer M, Choi HK, et al. Hyaluronic acid injections relieve knee pain. J Fam Pract 2005; 54: 758–67PubMed
44.
Bjordal JM, Klovning A, Ljunggren AE, et al. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2006; 11(2): 125–38PubMedCrossRef
45.
Cohen MA, Shiroky JB, Ballachey ML, et al. Double-blind randomised trial of intra-articular (I/A) hyaluronate in the treatment of osteoarthritis of the knee [abstract]. Arthritis Rheum 1994; 37Suppl. 9: R31
46.
Dixon AS, Jacoby RK, Berry H, et al. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin 1988; 11: 205–13PubMedCrossRef
47.
Wu JJ, Shih LY, Hsu HC, et al. The double-blind test of sodium hyaluronate (ARTZ) on osteoarthritis knee. Zhonghua Yi Xue Za Zhi (Taipei) 1997; 59: 99–106
48.
Corrado EM, Peluso GF, Gigliotti S, et al. The effects of intra-articular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evaluations. Eur J Rheumatol Inflamm 1995; 15: 47–56
49.
Creamer P, Sharif M, George E, et al. Intra-articular hyaluronic acid in osteoarthritis of the knee: an investigation into mechanisms of action. Osteoarthritis Cartilage 1994; 2: 133–40PubMedCrossRef
50.
Dougados M, Nguyen M, Listrat V, et al. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo controlled trial. Osteoarthritis Cartilage 1993; 1: 97–103PubMedCrossRef
51.
Puhl W, Bernau A, Greiling H, et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter double-blind study. Osteoarthritis Cartilage 1993; 1: 233–41PubMedCrossRef
52.
Raynauld JP, Torrance G, Band P, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage 2002; 10: 506–17PubMedCrossRef
53.
Kahan A, Lleu PL, Salin L. Prospective randomized study comparing the medico-economic benefits of hylan G-F 20 vs. conventional treatment in knee osteoarthritis. Joint Bone Spine 2003; 70: 276–81PubMedCrossRef
54.
Dickson DJ, Hosie G, English JR. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Clin Res 2001; 4: 41–52
55.
Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995; 3: 213–25PubMedCrossRef
56.
Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med 2002; 162: 292–8PubMedCrossRef
57.
Caborn D, Rush J, Lanzer W, et al. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol 2004; 31: 333–43PubMed
58.
Frizziero L, Pasquali-Ronchetti I. Intra-articular treatment of osteoarthritis of the knee: an arthroscopic and clinical comparison between sodium hyaluronate (500–730 kDa) and methylprednisolone acetate. J Orthopaed Traumatol 2002; 3: 89–96CrossRef
59.
Tascioglu F, Oner C. Efficacy of intra-articular sodium hyaluronate in the treatment of knee osteoarthritis. Clin Rheumatol 2003; 22: 112–7CrossRef
60.
Pietrogrande V, Melanotte PL, D’Agnolo B, et al. Hyaluronic acid versus methylprednisolone intra-articularly injected for treatment of osteoarthritis of the knee. Curr Ther Res 1991; 50: 691–701
61.
Ozturk C, Atamaz F, Hepguler S, et al. The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. Rheum Int Clin Exper Investig 2005; 26: 314–9
62.
Kotevoglu N, Iybozkurt PC, Hz O, et al. A prospective randomized controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int 2006; 26: 325–30PubMedCrossRef
63.
Karatosun V, Unver B, Gocen Z, et al. Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee: a prospective, randomized, double-blind study with long term follow-up. Clin Exp Rheumatol 2005; 23: 213–8PubMed
64.
Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 1999; 21: 1549–62PubMedCrossRef
65.
Pritchard CH, Sripada P, Bankes PF, et al. A retrospective comparison of the efficacy and tolerability of sodium hyaluronate and hylan G-F 20 in the treatment of osteoarthritis of the knee. J Musculoskel Res 2002; 6: 197–205CrossRef
66.
Waddell DD, Cefalu CA, Bricker DC. An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthritis. Curr Med Res Opin 2003; 19: 499–507PubMedCrossRef
67.
Waddell DD, Cefalu CA, Bricker DC. A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J Knee Surg 2005; 18: 7–15PubMed
68.
Raynauld JP, Goldsmith CH, Bellamy N, et al. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthritis Cartilage 2005; 13: 111–9PubMedCrossRef
69.
Kotz R, Kolarz G. Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles. Am J Orthop 1999; 28: 5–7PubMed
70.
Kolarz G, Kotz R, Hochmayer I. Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Semin Arthritis Rheum 2003; 32: 310–9PubMedCrossRef
71.
Scali JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long term study. Eur J Rheumatol Inflamm 1995; 15: 57–62
72.
Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin 2003; 19: Pl–6
73.
Gray RG, Gottlieb NL. Intra-articular corticosteroids. An updated assessment. Clin Orthop Rel Res 1983; 177: 235–63
74.
75.
Jackson DW, Evans NA, Thomas BM. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg Am 2002; 84-A: 1522–7PubMed
76.
Schumacher Jr HR. Aspiration and injection therapies for joints. Arthritis Rheum 2003; 49: 413–20PubMedCrossRef
77.
Waddell DD, Bricker DC. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J Surg Orthop Adv 2006; 15: 53–9PubMed
78.
Gossec L, Dougados M. Do intra-articular therapies work and who will benefit most? Best Pract Res Clin Rheumatol 2006; 20: 131–44PubMedCrossRef
79.
Torrance GW, Raynauld JP, Walker V, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 2 of 2): economic results. Osteoarthritis Cartilage 2002; 10: 518–27PubMedCrossRef
80.
Yen ZS, Lai MS, Wang CT, et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J Rheumatol 2004; 31: 1797–803PubMed
81.
Kemper F, Gebhardt U, Meng T, et al. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin 2005; 21: 1261–9PubMedCrossRef
82.
Waddell DD, Bricker D. Hylan G-F 20 reduces the probability of progression to total knee replacement in knee osteoarthritis [abstract]. Arthritis Rheum 2001; 44: S49
83.
Forster MC, Straw R. A prospective randomised trial comparing intra-articular Hyalgan injection and arthroscopic washout for knee osteoarthritis. Knee 2003; 10: 291–3PubMedCrossRef
84.
Rahme E, Barkun AN, Adam V, et al. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs. Drug Saf 2004; 27: 1019–42PubMedCrossRef
85.
Spiegel BM, Targownik L, Dulai GS, et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795–806PubMed
86.
Akarca US. Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. Curr Pharm Des 2005; 11: 1779–93PubMedCrossRef
87.
Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data. Vital Health Stat 2004; 156: 1–198
88.
The Institute of Orthopaedic Enlightenment. The ortho factbook: 2002–2003 series, US. 3rd ed. Chagrin Falls (OH): Knowledge Enterprises Inc., 2002
89.
Burns AW, Bourne RB, Chesworth BM, et al. Cost effectiveness of revision total knee arthroplasty. Clin Orthop Relat Res 2006; 446: 29–33PubMedCrossRef
90.
Waddell D, Rein A, Panarites C, et al. Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting. Am J Manag Care 2001; 7: 981–91PubMed
91.
Ong KL, Mowat FS, Chan N, et al. Economic burden of revision hip and knee arthroplasty in Medicare enrollees. Clin Orthop Relat Res 2006; 446: 22–8PubMedCrossRef
92.
Bourne RB, Maloney WJ, Wright JG. An AOA critical issue: the outcome of the outcomes movement. J Bone Joint Surg Am 2004; 86-A: 633–40PubMed
93.
Kurtz S, Mowat F, Ong K, et al. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am 2005; 87: 1487–97PubMedCrossRef
94.
Bell M, Fallaha M, Lenczner E, et al. Viscosupplementation with hylan G-F 20 in total knee replacement candidates: an effective pain management therapy that may delay surgery [abstract]. Osteoarthritis Cartilage 1999; 7Suppl. A: S30
95.
Marshall KW. Hylan G-F 20 (Synvisc®) salvage of patients failing a standardized arthroscopic debridement treatment algorithm. Poster presentation at the European Federation of National Association of Orthopedics Meeting; 1999 Jun 3–4; Brussels
96.
Waddell DD, Bricker DC. Total knee replacement delayed with hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm 2007; 13: 113–21PubMed
Metadata
Title
Viscosupplementation with Hyaluronans for Osteoarthritis of the Knee
Clinical Efficacy and Economic Implications
Author
Dr David D. Waddell
Publication date
01-08-2007
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2007
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200724080-00002

Other articles of this Issue 8/2007

Drugs & Aging 8/2007 Go to the issue

Original Research Article

Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs

Review Article

Community and Long-Term Care Management of Parkinson’s Disease in the Elderly

Current Opinion

Is Combination Therapy with Inhaled Anticholinergics and β2-Adrenoceptor Agonists Justified for Chronic Obstructive Pulmonary Disease?

Original Research Article

Withdrawal of Fall-Risk-Increasing Drugs in Older Persons

Review Article

Targeting Vascular Endothelial Growth Factor
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits